Wealth Enhancement Advisory Services LLC Reduces Stock Position in Humana Inc. (NYSE:HUM)

Wealth Enhancement Advisory Services LLC trimmed its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 26.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,438 shares of the insurance provider's stock after selling 2,272 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Humana were worth $1,633,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after acquiring an additional 1,751,857 shares during the last quarter. Dodge & Cox increased its stake in Humana by 106.7% in the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after acquiring an additional 5,264,045 shares during the last quarter. Pzena Investment Management LLC increased its stake in Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after acquiring an additional 1,103,132 shares during the last quarter. Geode Capital Management LLC increased its stake in Humana by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after acquiring an additional 63,562 shares during the last quarter. Finally, Invesco Ltd. increased its stake in Humana by 29.8% in the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock worth $608,348,000 after acquiring an additional 550,692 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

HUM stock traded up $3.20 during trading on Friday, hitting $230.36. The stock had a trading volume of 3,452,189 shares, compared to its average volume of 1,785,998. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a twelve month low of $212.45 and a twelve month high of $406.46. The stock has a market capitalization of $27.80 billion, a P/E ratio of 23.15, a PEG ratio of 2.05 and a beta of 0.43. The company's 50-day moving average price is $253.49 and its two-hundred day moving average price is $265.11.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $7.23 EPS. As a group, research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.54%. Humana's payout ratio is currently 25.04%.

Analysts Set New Price Targets

HUM has been the subject of a number of research reports. Guggenheim initiated coverage on Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective for the company. Robert W. Baird upped their price objective on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. Truist Financial cut their price objective on Humana from $325.00 to $305.00 and set a "hold" rating for the company in a report on Monday, May 12th. Barclays cut their price objective on Humana from $322.00 to $273.00 and set an "equal weight" rating for the company in a report on Monday, June 2nd. Finally, Wall Street Zen upgraded Humana from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Sixteen equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $284.48.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.